skip to content
CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Preview this item
ClosePreview this item
Checking...

CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Author: CADTH Canadian Drug Expert Committee,; Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : CADTH, February 21, 2018.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English : Version 1.0
Summary:
The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics for the treatment of moderate-to-severe plaque psoriasis. Treatment should be discontinued if a response to treatment  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: CADTH Canadian Drug Expert Committee,; Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1090385001
Notes: "Final."
Description: 1 online resource (1 PDF file (9 pages)).
Series Title: Common drug review clinical review report.
Other Titles: Guselkumab (Tremfya -- janssen inc.)

Abstract:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics for the treatment of moderate-to-severe plaque psoriasis. Treatment should be discontinued if a response to treatment with guselkumab has not been demonstrated after 16 weeks.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1090385001> # CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
    library:oclcnum "1090385001" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8985178467#Topic/interleukin_23_subunit_p19_therapeutic_use> ; # Interleukin-23 Subunit p19--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8985178467#Topic/interleukin_23_subunit_p19_economics> ; # Interleukin-23 Subunit p19--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8985178467#Topic/antibodies_monoclonal_economics> ; # Antibodies, Monoclonal--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8985178467#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/8985178467#Topic/antibodies_monoclonal_therapeutic_use> ; # Antibodies, Monoclonal--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8985178467#Topic/insurance_health_reimbursement> ; # Insurance, Health, Reimbursement
    schema:about <http://experiment.worldcat.org/entity/work/data/8985178467#Topic/drug_costs> ; # Drug Costs
    schema:about <http://experiment.worldcat.org/entity/work/data/8985178467#Topic/psoriasis_drug_therapy> ; # Psoriasis--drug therapy
    schema:alternateName "Guselkumab (Tremfya -- janssen inc.)" ;
    schema:author <http://experiment.worldcat.org/entity/work/data/8985178467#Organization/cadth_canadian_drug_expert_committee> ; # CADTH Canadian Drug Expert Committee,
    schema:bookEdition "Version 1.0." ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8985178467#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2018" ;
    schema:description "The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics for the treatment of moderate-to-severe plaque psoriasis. Treatment should be discontinued if a response to treatment with guselkumab has not been demonstrated after 16 weeks."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8985178467> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8985178467#Series/cadth_common_drug_review> ; # CADTH common drug review
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8985178467#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:name "CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy."@en ;
    schema:productID "1090385001" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK532985/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1090385001> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8985178467#Organization/cadth_canadian_drug_expert_committee> # CADTH Canadian Drug Expert Committee,
    a schema:Organization ;
    schema:name "CADTH Canadian Drug Expert Committee," ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1090385001> ; # CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1090385001> ; # CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/antibodies_monoclonal_economics> # Antibodies, Monoclonal--economics
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/antibodies_monoclonal_therapeutic_use> # Antibodies, Monoclonal--therapeutic use
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/insurance_health_reimbursement> # Insurance, Health, Reimbursement
    a schema:Intangible ;
    schema:name "Insurance, Health, Reimbursement"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/interleukin_23_subunit_p19_economics> # Interleukin-23 Subunit p19--economics
    a schema:Intangible ;
    schema:name "Interleukin-23 Subunit p19--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/interleukin_23_subunit_p19_therapeutic_use> # Interleukin-23 Subunit p19--therapeutic use
    a schema:Intangible ;
    schema:name "Interleukin-23 Subunit p19--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/psoriasis_drug_therapy> # Psoriasis--drug therapy
    a schema:Intangible ;
    schema:name "Psoriasis--drug therapy"@en ;
    .

<http://www.worldcat.org/title/-/oclc/1090385001>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1090385001> ; # CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
    schema:dateModified "2019-12-06" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.